2025-12-03 - Analysis Report
Okay, let's break down the analysis of Teladoc Health Inc. (TDOC).

**0) Report Structure:**

The report will follow this structure:

1.  **Return Rate Comparison:** TDOC vs. S&P 500 (VOO)
2.  **Recent Stock Price Fluctuations:** Simple Moving Averages (SMA)
3.  **Technical Indicators Analysis:** RSI, PPO, MRI, Hybrid Signal, Divergence Change, Expected Return
4.  **News & Events + Analyst Opinions:** Summarize key headlines and consensus
5.  **Earnings Analysis:** Review EPS and Revenue data
6.  **Financial Information:** Review Profit Margin and ROE data
7.  **Comprehensive Analysis:** Overall summary and assessment

**1) Return Rate Comparison: TDOC vs. VOO**

*   **Ticker:** TDOC
*   **Company Name:** Teladoc Health Inc. (A telehealth company providing virtual medical care.)
*   **TDOC Cumulative Return:** -62.80%
*   **VOO Cumulative Return:** 101.40%
*   **Divergence:** -165.9 (Relative Divergence: 0.1)

**Analysis:** Teladoc has significantly underperformed the S\&P 500 (VOO). The divergence of -165.9 indicates a substantial difference in cumulative returns, and the relative divergence of 0.1 suggests that this difference is near the minimum historically observed.

**Alpha, Beta Analysis:**

|            | CAGR      | MDD     | Alpha    | Beta   | Cap(B) |
| :--------- | :-------- | :------ | :------- | :----- | :----- |
| 2015-2017  | 77.0%     | 70.4%   | 51.0%    | -0.1   | 6.2    |
| 2016-2018  | 101.0%    | 69.4%   | 86.0%    | -0.1   | 8.8    |
| 2017-2019  | 141.0%    | 73.8%   | 118.0%   | 0.3    | 14.8   |
| 2018-2020  | 105.0%    | 80.9%   | 81.0%    | 0.3    | 35.5   |
| 2019-2021  | -78.0%    | 80.9%   | -125.0%  | 0.3    | 16.3   |
| 2020-2022  | -252.0%   | 85.9%   | -251.0%  | -0.9   | 4.2    |
| 2021-2023  | -315.0%   | 85.9%   | -316.0%  | -1.8   | 3.8    |
| 2022-2024  | -93.0%    | 85.9%   | -113.0%  | -1.9   | 1.6    |
| 2023-2025  | -34.0%    | 81.6%   | -99.0%   | -0.8   | 1.3    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows a significant decline in recent periods, indicating poor performance.
*   **MDD (Maximum Drawdown):** High MDD values consistently indicate substantial risk and volatility.
*   **Alpha:** Consistently negative in recent years, suggesting underperformance relative to the benchmark.
*   **Beta:** Beta has fluctuated but has been negative recently, suggesting an inverse relationship with the market.
*   **Cap(B):** Market Cap decreasing over time, indicating lost value.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 7.525
*   **Last Market:** Price = 7.53, Previous Close = 7.44, Change = 1.21%
*   **5-day SMA:** 7.455
*   **20-day SMA:** 7.384
*   **60-day SMA:** 8.0146

**Analysis:** The current price is slightly above the 5-day and 20-day SMAs, but still below the 60-day SMA. This suggests a possible short-term uptrend, but the longer-term trend may still be down. The recent price change reflects some upward momentum.

**3) Technical Indicators Analysis:**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 50.53
*   **PPO (Percentage Price Oscillator):** 0.96
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.1 (Short-term decline)
*   **Expected Return (%):** -10152.0% (Significant underperformance expected compared to S&P 500)

**Analysis:**

*   **MRI:** The high MRI suggests it may be a good investment opportunity.
*   **RSI:** An RSI around 50 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** A positive PPO indicates that the shorter-term moving average is above the longer-term moving average, suggesting a potential uptrend.
*   **Hybrid Signal:** The Hybrid Signal suggests a strong buy with the current settings.
*   **Divergence Change:** The recent decline in relative divergence reinforces the recent underperformance.
*   **Expected Return:** The extremely negative expected return is a major red flag.

**4) Recent News & Significant Events:**

*   **Valuation Assessments:** Several articles focus on Teladoc's valuation, particularly after the TytoCare integration and recent share price weakness.
*   **Earnings Decline:** News highlights concerns about the recent earnings decline.
*   **Analyst Opinions:** Articles discuss whether to buy, hold, or sell TDOC post Q3 results, suggesting mixed opinions.
*   **Fading Hope:** One article suggests a lack of optimism regarding Teladoc's future.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.65 (Hold)
*   **Opinions:** 21
*   **Target Price:** Avg: 9.21 / High: 12.00 / Low: 7.00

**Analysis:** Analyst consensus is a "Hold" rating, suggesting no strong buy or sell recommendation. The average target price is slightly above the current price, but the range indicates uncertainty.

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
| :--------- | :---- | :----------- |
| 2025-10-30 | -0.28 | 0.63 B$      |
| 2025-07-30 | -0.19 | 0.63 B$      |
| 2025-05-01 | -0.53 | 0.63 B$      |
| 2024-10-31 | -0.19 | 0.64 B$      |
| 2025-10-30 | -0.19 | 0.64 B$      |

**Analysis:** Teladoc has consistently reported negative EPS (Earnings Per Share). Revenue has been relatively stable around $0.63-0.64 billion, but it isn't translating into profitability. The negative EPS trend is concerning.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-09-30   | $0.63B    | 70.12%        |
| 2025-06-30   | $0.63B    | 69.85%        |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
| :----------- | :-------- | :-------- |
| 2025-09-30   | $1.39B    | -3.56%    |
| 2025-06-30   | $1.42B    | -2.30%    |
| 2025-03-31   | $1.43B    | -6.52%    |
| 2024-12-31   | $1.49B    | -3.25%    |
| 2024-09-30   | $1.51B    | -2.21%    |

**Analysis:**

*   **Profit Margin:** While the "Profit Margin" numbers shown are high, they are likely a misunderstanding of the data. The negative ROE suggests this is not the true profit margin.
*   **ROE (Return on Equity):** Consistently negative ROE indicates that Teladoc is not generating profits from shareholder equity. Equity is also decreasing.

**7) Comprehensive Analysis:**

*   **Underperformance:** Teladoc has significantly underperformed the S&P 500.
*   **Financial Concerns:** Negative EPS and ROE, combined with declining equity, raise serious concerns about the company's financial health.
*   **Mixed Signals:** While some technical indicators like the PPO and MRI suggest potential opportunities, the overwhelmingly negative expected return and analyst consensus of "Hold" indicate caution.
*   **Valuation Uncertainty:** News articles highlight ongoing debates about Teladoc's valuation, further emphasizing the uncertainty surrounding the stock.

**Overall Assessment:**

Based on the provided data, Teladoc Health (TDOC) appears to be a **high-risk investment.** The company is facing significant financial challenges, as evidenced by negative earnings and returns. While there may be short-term opportunities based on technical indicators or valuation assessments, the long-term outlook remains uncertain. A cautious approach is warranted.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.